The Papillomavirus E2 proteins  by McBride, Alison A.
Virology 445 (2013) 57–79Contents lists available at ScienceDirectVirology0042-68
http://d
n Corr
20892-3
E-mjournal homepage: www.elsevier.com/locate/yviroThe Papillomavirus E2 proteins
Alison A. McBride n
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USAa r t i c l e i n f o
Available online 10 July 2013
Keywords:
HPV
Papillomavirus
E2
Replication
Transcription
Tethering
Genomics
Structure
Mutation22/$ - see front matter Published by Elsevier
x.doi.org/10.1016/j.virol.2013.06.006
espondence to: Room 3W20B.4, Building 33, 3
209, USA.
ail address: amcbride@nih.gova b s t r a c t
The papillomavirus E2 proteins are pivotal to the viral life cycle and have well characterized functions in
transcriptional regulation, initiation of DNA replication and partitioning the viral genome. The E2
proteins also function in vegetative DNA replication, post-transcriptional processes and possibly
packaging. This review describes structural and functional aspects of the E2 proteins and their binding
sites on the viral genome. It is intended to be a reference guide to this viral protein.
Published by Elsevier Inc.Introduction
The full-length E2 protein is an essential regulatory protein
encoded by all papillomaviruses. In addition, all viruses have the
potential to encode at least one shorter E2 species. All E2 proteins
are sequence speciﬁc DNA binding proteins that bind to 12 bp
motifs located mostly within the Upstream Regulatory Region
(URR) of the viral genomes. E2 proteins are multifunctional and
involved in many viral processes, mostly associated with tran-
scription and replication of the viral genome. They are expressed
at early and intermediate stages of the viral life cycle. This review
is intended to be an encyclopedic overview of the structure and
function of the E2 proteins.E2 isoforms and transcripts
E2 protein isoforms
The full-length E2 protein expressed from the entire E2 open
reading frame (ORF) consists of a conserved N-terminal terminal
“transactivation” domain of about 200 amino acids linked to a C-
terminal DNA binding/dimerization domain of about 100 amino
acids. The two domains are connected by a ﬂexible linker
sequence, often called the “hinge” (Giri and Yaniv, 1988; McBride
et al., 1989b, 1988), which varies in length and sequence composi-
tion among different genera of papillomaviruses (see Fig. 1A).Inc.
3 North Drive, Bethesda, MDAll PVS have the potential to encode shorter E2 forms that
contain the C-terminal domain, the hinge region and a 10–13
residue peptide from an upstream ORF. These E2 fusion proteins
are encoded by spliced messages that link sequences from an
alternative reading frame in the E1 region of the genome (desig-
nated E8) to the C-terminus of E2. These proteins have been
alternatively named E84E2, E84E2C, E14E2, E1M4E2 and E94E2,
and are shown in Fig. 1A. Invariably, the shorter forms of E2
function as repressors of viral transcription and replication.
The relative abundance of the different E2 isoforms has been
determined in BPV-1 infected cells; E2, E2-TR and E84E2 are
expressed in ratios 1:10:3, respectively (Hubbert et al., 1988). This
means that most full-length E2 proteins are present as hetero-
dimers. These heterodimers can support transcription and replica-
tion initiation, but not partitioning of viral genomes (Kurg et al.,
2006, 2009, 2010).E2 encoding transcripts
In the alpha-PVs, such as HPV16, the full length E2 protein is
encoded from spliced messages expressed from either the early or
late promoters (Johansson and Schwartz, 2013). These transcripts
are shown in Fig. 1B. In undifferentiated cells, E2 encoding mRNAs
are transcribed from the early promoter and terminate at the early
polyadenylation site (pAE). As cells differentiate in the mid-layers
of the epithelium, the late promoter becomes activated and
transcribes an intermediate class of messages that still use the
early polyadenylation signal (Johansson and Schwartz, 2013).
These transcripts encode high levels of E2 that are required for
vegetative viral DNA replication (Ozbun and Meyers, 1998).
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Fig. 1. E2 isoforms and transcripts. (A) Isoforms. The two conserved domains of the full-length E2 protein, encoded by all PVs, are shown in green at the top. The region
between the domains is of variable length and is named the Hinge. Many PVs have been shown to encode an E84E2 (or equivalent) repressor form as shown and all PVs
encode homologous sequences and splice donor/acceptor sites. BPV1 encodes two repressor forms. Some examples of E2 repressor proteins are shown. (B) E2 transcripts.
The URR and early region of an alpha-PV genome is shown. In the lower layers of a papilloma, mRNAs are transcribed from the early promoter, PE, and terminated at the
early polyadenylation signal, pAE. At the next stage of differentiation, the late promoter is activated, but messages are still truncated at pAE. Transcripts encoding the full-
length E2 protein are transcribed from the early and late promoters (reviewed in Johansson and Schwartz, 2013; Schwartz, this issue). It is not clear whether both promoters
can transcribe the E84E2 mRNAs, though it seems most likely that they would be transcribed from the early promoter in undifferentiated cells. The origin of replication (ori)
is indicated with the E1 binding site shown as a blue square and E2 binding sites as cyan circles.
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a short exon encoding E8 spliced to the major splice acceptor in
the middle of the E2 ORF (Stubenrauch et al., 2000). These mRNAs
species use the same splice acceptor as the E14E4 proteins and a
splice donor located in the 5′ region of the E1 ORF (about 400
nucleotides from the E1 start codon). Transcripts encoding shorter
E2 forms have been mapped in BPV1 (Choe et al., 1989; Hubbert
et al., 1988; Lambert et al., 1989), SfPV1 (Jeckel et al., 2003), HPV11
(Chiang et al., 1991), HPV16 (Lace et al., 2008) and HPV31
(Stubenrauch et al., 2000). However, analysis of sequences in the
PaVE database reveals that all PVs have the potential to encode the
equivalent of an E84E2 transcript. A more extensive description of
E8 sequences is presented below.
In BPV1, a delta-PV, the E2 proteins can be expressed from
spliced messages similar to those encoded by the alpha-PVs, but
also from additional promoters located in the early region of the
genome (Choe et al., 1989; Lambert et al., 1989; Spalholz et al.,
1991; Vaillancourt et al., 1990). BPV1 encodes a second repressor
protein, designated E2-TR, that is transcribed from an early region
promoter (P3080) and initiated from an internal ATG in the E2
ORF. Three distinct E2 proteins corresponding to full-length E2,
E84E2 and E2-TR have been detected in BPV1 infected cells
(Hubbert et al., 1988). Papilllomaviruses from the Delta genus are
unique in their ability to cause ﬁbropapillomas. Their unusual
transcriptional pattern might reﬂect this additional tropism for
ﬁbroblasts.Additional E2-derived messages have been described. Two
differentiation-dependent transcripts that fuse either 12 or 116
residues from the N-terminus of HPV16 E2 onto E4 have been
detected (Tan et al., 2012).E2 functions
transcription
The E2 proteins are the main transcriptional regulators of the
papillomaviruses (Chin et al., 1988; Choe et al., 1989; Cripe et al.,
1987; Lambert et al., 1987; Phelps and Howley, 1987; Spalholz
et al., 1985). The E2 proteins function primarily by recruiting
cellular factors to the viral genomes, which activate or repress
transcriptional processes. The E2 proteins bind speciﬁcally to
sequence motifs in the viral genome and can activate or repress
transcription, depending on the context of these binding sites and
nature of the associated cellular factors. E2 binding sterically
hinders the binding of cellular factors such as Sp1 and TBP to
proximal promoter elements in the viral genome (Bernard et al.,
1989; Dong et al., 1994; Dostatni et al., 1991; Hou et al., 2000;
May et al., 1994; Romanczuk et al., 1990; Stubenrauch et al., 1996;
Stubenrauch and Pﬁster, 1994; Tan et al., 1994). In many viruses,
the full-length E2 protein either activates or represses viral
transcription in a dose dependent manner (Bouvard et al., 1994;
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1987). Later studies demonstrated that E2 represses transcription
by recruiting factors that manipulate cellular chromatin processes
(Nishimura et al., 2000; Schweiger et al., 2007; Smith et al., 2010;
Wu et al., 2006).
The shorter forms of E2 can act as repressors of E2 function.
Repression can be mediated by competition for binding to E2
binding sites (Lambert et al., 1987; Lim et al., 1998; Monini et al.,
1993), and by recruitment of repressor complexes by the E8-
derived peptide to viral DNA (Ammermann et al., 2008; Fertey
et al., 2010; Powell et al., 2010). Expression of shorter forms of E2
can repress transcriptional activation by dimerization with full-
length E2 (Barsoum et al., 1992) but heterodimers with just one
activation domain can also activate transcription (Kurg et al.,
2006).
E2 protein functions are occasionally disrupted by mutation or
integration of the viral genome (Schwarz et al., 1985). This
inactivation leads to alleviation of E2-mediated repression and
increased expression of the E6 and E7 genes (Bernard et al., 1989;
Thierry and Howley, 1991; Thierry and Yaniv, 1987), contributing
to malignant progression in “high risk” PV infection. Restoration of
E2 expression in cervical cancer derived lines leads to senescence
(Goodwin et al., 2000) as HPV-associated cancer cells are addicted
to, and dependent on, E6 and E7 expression (Desaintes et al., 1997;
Dowhanick et al., 1995; Hwang et al., 1993).Initiation of viral DNA replication
There are three modes of replication in the papillomavirus life
cycle. First, limited and unlicensed genome ampliﬁcation occurs
when a viral particle ﬁrst enters the host cell. In the second phase,
the viral genome is maintained at a constant copy number in the
proliferating basal cells of a papilloma. This phase requires both
genome replication and partitioning. In the third phase, genomes
are ampliﬁed in differentiated cells to produce progeny virions.
E2 participates in the initiation of viral DNA replication by
loading the E1 helicase onto the replication origin (Mohr et al.,
1990; Sanders and Stenlund, 2000). The replication origin contains
an E1 binding site, an A/T rich region and at least one E2 binding
site (Ustav et al., 1993; Ustav et al., 1991). E1 is the primary
replication protein but E2 enhances and supports the functions of
E1 (Frattini and Laimins, 1994; Mohr et al., 1990). After E1 is loaded
it converts to a double-hexameric helicase and E2 is displaced
(Sanders and Stenlund, 1998). E2 also displaces nucleosomes from
the origin to alleviate repression (Li and Botchan, 1994).Table 1
Chromosomal Targets of Viral Tethering Proteins
PV Genus Predominant Mitotic Chromosome Binding
Phenotype
Proposed
Alpha • Binding to chromosomes only readily observed by
immunoﬂuorescence at late stages of mitosis.
• Binding to rDNA loci observed in pre-extracted cells
Brd4, mit
spindle, C
TopBP1,
Beta • Prominent binding to pericentromeric regions and
rDNA loci
• When E2-rDNA association is disrupted,
chromosomal foci of Brd4 can be observed.
Brd4, rDN
pericentr
regions
Delta, Mu and
others
• E2 and Brd4 form distinct foci on arms of most host
chromosomes
• At high levels, some E2 observed at mid-body in late
mitosis
Brd4, ChLThe E84E2 transcriptional repressor is a potent repressor of
viral DNA replication (Lace et al., 2008; Zobel et al., 2003), and this
involves the recruitment of cellular corepressor factors
(Ammermann et al., 2008). E84E2 modulates the levels of replica-
tion in the maintenance phase of replication in HPV16, HPV18 and
HPV31 (Kurg et al., 2010; Lace et al., 2008; Stubenrauch et al.,
2000), but only appears to be essential for episomal maintenance
in HPV31 (Lace et al., 2008; Stubenrauch et al., 2000). In BPV1,
elimination of the E2-TR repressor increases genome copy number
(Lambert et al., 1990; Riese et al., 1990) and removal of both
repressors results in a replication defect. However, SfPV1 (formerly
CRPV) genomes that are defective for E84E2 (aka E94E2C)
expression can replicate and induce tumors in rabbits at levels
comparable to that of wildtype genomes (Jeckel et al., 2003).
Viral DNA replication takes place in nuclear foci and the
formation of these foci are dependent on the E2 protein (Fradet-
Turcotte et al., 2011; Reinson et al., 2013; Sakakibara et al., 2011;
Swindle et al., 1999). Viral DNA replication and viral proteins
induce a DNA damage response within these foci that is thought to
be important to recruit cellular repair proteins to synthesize viral
DNA (Fradet-Turcotte et al., 2011; Gillespie et al., 2012; Moody and
Laimins, 2009; Reinson et al., 2013; Sakakibara et al., 2011;
Sakakibara et al., in press).
Genome maintenance, partitioning and tethering
E1 and E2 support transient replication of replicons containing
the minimal origin of replication, but these replicons are quickly
lost. Persistent and stable maintenance of replicons require addi-
tional E2 binding sites in cis to the origin (Piirsoo et al., 1996). For
BPV1, at least eight E2 binding sites are required for stable
episomal maintenance (Piirsoo et al., 1996), but three E2 binding
sites are sufﬁcient for maintenance of HPV18 derived replicons
(van Doorslaer et al., 2013) or for episomal maintenance of HPV31
genomes with mutations in individual E2 binding sites
(Stubenrauch et al., 1998b). The E2 protein tethers the viral
genomes through these sites to the host chromosomes in mitosis
to facilitate retention, maintenance and partitioning of the viral
genome (Bastien and McBride, 2000; Ilves et al., 1999; Lehman and
Botchan, 1998; Skiadopoulos and McBride, 1998). The E2 DNA
binding domain binds to binding sites in the viral genome
and other regions of E2 (such as the transactivation domain)
tether the genome to mitotic chromosomes through protein-
protein interactions. Heterodimers formed by long and short forms
of E2 can support initiation of replication but they are defective for
partitioning (Kurg et al., 2006, 2009, 2010).targets Reference
otic
hLR1,
(Donaldson et al., 2007; Gammoh et al., 2006;
McPhillips et al., 2006; Parish et al., 2006; Van Tine et al., 2004)
A,
omeric
(McBride and van Doorslaer, 2013; Oliveira et al., 2006; Poddar et al.,
2009; Sekhar and McBride, 2012; Sekhar et al., 2010)
R1, Mklp2 (Baxter et al., 2005; Ilves et al., 2006; Parish et al., 2006;
You et al., 2004; Yu et al., 2007)
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regions of mitotic chromosomes (Oliveira et al., 2006). As shown in
Table 1, E2 proteins from viruses such as BPV1 and HPV1 bind as
punctate foci all over the arms of most mitotic chromosomes
(Oliveira et al., 2006; Skiadopoulos and McBride, 1998). On the
other hand, E2 proteins from Beta-PVs bind most prominently to
pericentromeric regions of chromosomes that overlap the loci for
the ribosomal RNA genes (Oliveira et al., 2006; Poddar et al., 2009).
The alpha-PVs are difﬁcult to detect by immunoﬂuorescence
throughout mitosis on condensed chromosomes, though they are
readily detected bound to host chromosomes in telophase
(Donaldson et al., 2007; Gammoh et al., 2006; McPhillips et al.,
2006). Compared to other E2 proteins, the alpha PV E2s are not
tightly bound to host chromatin, even in interphase (McPhillips
et al., 2006). When cells are pre-extracted before ﬁxation, most E2
is eluted and the remaining E2 is observed bound to pericentro-
meric regions of mitotic chromosomes similar to the Beta-PV E2
proteins (Oliveira et al., 2006). It is notable that the three different
phenotypes of mitotic chromosome binding correspond well to
the phylogeny of papillomaviruses: these groups consist of the
Alpha-PVs, the Beta and Gamma PVs, and a diverse group of
viruses from the delta (BPV1), mu (HPV1), kappa (OcPV1 and
SfPV1) and other genera.
One of the best studied tethering targets on the mitotic
chromosomes is the chromatin adapter protein, Brd4 (Baxter
et al., 2005; Ilves et al., 2006; You et al., 2004). Many PV E2
proteins colocalize with Brd4 in punctate speckles on mitotic
chromatin (McPhillips et al., 2006; Oliveira et al., 2006) and these
E2 proteins stabilize the association of Brd4 with chromatin
(McPhillips et al., 2006, 2005). Disruption of the E2-Brd4 associa-
tion displaces genomes from chromosomes (Abbate et al., 2006)
and results in a loss of BPV1 genomes from infected cells (You
et al., 2005). Two highly conserved residues in the E2 transactiva-
tion domain, R37 and I73, mediate the interaction with theHPV16 HPV1
HPV18 HPV
Fig. 2. Structures of the transactivation and DNA binding domains. (A) Transactivation
Structures PDB: 2JEU (BPV1), PDB: 1R6K (HPV11) and PDB: 1DTO (HPV16) were rendered
proteins are shown. Structures PDB: 1JJ4 (HPV18), PDB: 2AYB (HPV6) and PDB: 2BOP (BC-terminus of the Brd4 protein (Abbate et al., 2006; Baxter et al.,
2005; Senechal et al., 2007; You et al., 2004). All papillomavirus E2
proteins bind Brd4 to regulate transcription but they are not all
readily observed bound to mitotic chromosomes with Brd4
(McPhillips et al., 2006).
The diverse group of E2 proteins described above, best represented
by BPV1 and HPV1, bind with high afﬁnity to Brd4 through the
transactivation domain and both proteins are easily detected coloca-
lized in punctate speckles on mitotic chromosomes. In contrast, as
described above, the beta-PV E2 proteins bind strongly to pericen-
tromeric regions of mitotic chromosomes and do not colocalize with
Brd4 at this location (Poddar et al., 2009). The Beta-PV E2 proteins
require only the E2 DNA binding domain and a short phosphorylated
peptide from the hinge region to bind to mitotic chromosomes
(Sekhar and McBride, 2012; Sekhar et al., 2010). However, the beta
E2 proteins can bind Brd4 with high afﬁnity and when the chromo-
somal binding peptide in the E2 hinge is mutated Brd4 is observed on
foci on mitotic chromosomes (McBride and van Doorslaer, 2013).
Alpha PV E2s bind to Brd4 relatively weakly and cannot be
easily detected on condensed chromosomes throughout mitosis
(McPhillips et al., 2006). However, Brd4 localizes to replication foci
formed by the E1 and E2 proteins (Sakakibara et al., in press; Wang
et al., 2013), implying a role for Brd4 in replication. But HPV31
genomes that encode a mutated E2 protein (I73L) defective in Brd4
binding can still maintain extrachromosomal viral genomes and
undergo ampliﬁcation in differentiated keratinocytes (Senechal
et al., 2007; Stubenrauch et al., 1998b). Therefore the role of Brd4
in Alpha-PV E2 functions is still unclear. Several other cellular
targets such as the mitotic spindle (Dao et al., 2006), a mitotic
kinesin like protein, MKlp2(Yu et al., 2007), ChlR1 (an ATP-
dependent DNA helicase important for sister chromatid cohesion)
(Parish et al., 2006) and TopBP1 (Donaldson et al., 2007) have been
proposed to be important for tethering of Alpha-E2 proteins. This
information is summarized in Table 1.1 BPV1
6 BPV1
domain. The transactivation domain structures for three E2 proteins are shown.
in Pymol. (B) DNA binding domain. The DNA binding domain structures for three E2
PV1) were rendered in Pymol.
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E2 is almost certainly required for vegetative viral DNA ampli-
ﬁcation. E2-encoding transcripts are abundantly expressed from an
intermediate class of transcripts that use the late promoter and
early polyadenylation site (reviewed in (Johansson and Schwartz,
2013)) and the E2 protein is highly expressed in cells that are
amplifying the viral genome in the stratum spinosum of a bovine
wart (Burnett et al., 1990; Penrose and McBride, 2000) and see
Fig. 8. Vegetative ampliﬁcation can be induced by growth arrest inR12
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huge induction in E2 expression (Burnett et al., 1990). Using BPV1
encoding a temperature sensitive mutation in E2 (DiMaio and
Settleman, 1988), Alderborn et al. demonstrated that the replication,
but not transactivation function of E2 is required for genome
ampliﬁcation (Alderborn et al., 1992). Likewise, Stubenrauch et al.
showed that the transactivation function of E2 was not required for
HPV31 ampliﬁcation in differentiated keratinocytes (Stubenrauch
et al., 1998a). There is evidence that the mode of replication might
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(Flores and Lambert, 1997; Sakakibara et al., in press).
Packaging viral DNA
Early studies indicated that the E2 protein enhanced packaging
of viral genomes in virion particles (Zhao et al., 2000). The E2
protein is not absolutely required for this process, but one can
envisage several ways in which E2 could augment this process. For
example, E2 interacts with the minor capsid protein L2 at ND10
bodies, an association that could be important both for genome
establishment early in infection and enhancement of packaging
late in infection (Day et al., 2004; Day et al., 1998). The precise role
of E2 in these processes requires further investigation.
Post-transcriptional RNA processing
There are several indications that E2 regulates processing of
viral transcripts, though the exact mechanisms are not yet clear. E2
can promote late gene expression by depleting the polyadenyla-
tion complex, thus promoting read through of the early polyade-
nylation site and transcription of the late (Johansson et al., 2012).
This ﬁnding correlates well with the increase in E2 expression
during differentiation (see below). The E2 proteins of HPV5 and 16
can enhance the expression of, and interact with cellular SRDelta-
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et al., 2004) and Beta-PV E2 proteins localize to SR splicing
speckles (Lai et al., 1999; Sekhar et al., 2010).Growth inhibition and E2-mediated apoptosis
Expression of E2 is growth inhibitory to both HPV positive and
HPV negative cells. Only a few cell lines (CHO, CV1, C33-A, U2OS)
are able to tolerate low level E2 expression of any PV type. The
mechanism by which E2 induces growth arrest and senescence in
HPV positive cells is well established: E2 represses the early viral
promoter, thus down-regulating E6 and E7 expression. Most HPV
positive cancer cells, such as HeLa, are dependent on the viral
oncogenes for sustained growth (Desaintes et al., 1997; Dowhanick
et al., 1995; Goodwin and DiMaio, 2000; Goodwin et al., 1998,
2000). The mechanism by which E2 induces apoptosis in HPV-
negative cells is more controversial and involves both p53 depen-
dent and independent pathways (Webster et al., 2000), and the
interaction of E2 with caspase 8 (Demeret et al., 2003; Thierry and
Demeret, 2008). It is still not clear what role E2-mediated
apoptosis plays in the viral life-cycle but Bellanger et al. provide
a thorough review of this topic (Bellanger et al., 2011). Keratino-
cytes that are able to survive E2 expression develop phenotypes
typical of terminally differentiated cells, suggesting that E2 may
use this to promote viral late functions (Burns et al., 2010).PV E8
-PV E8 splice donor
splice donor
splice donorPV E8
all Lambda PVs are shown. Sequences were extracted from the PaVE database and
m http://www.geneious.com/.
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Fig. 6. E2 binding sites from nine genera of PVs. (A) E2 binding site sequence logos. E2 binding sites conforming to ACCN6GGT were extracted from the URR sequences in the PaVE
database from genera of PVs with more than six members. This amounted to 281 Alpha, 130 Beta, 127 Gamma, 68 Delta, 21 Lambda, 19 Xi, 13 Pi, 15 Epsilon and 48 Chi E2 consensus
motifs. Sequence logos were created for the recognition helix of sites from each genera using Weblogo (http://weblogo.berkeley.edu/logo.cgi) (Crooks et al., 2004). (B) E2 binding site
sequence logos for individual alpha E2 sites. Individual E2 binding sites sequences conforming to ACCN6GGTand corresponding to the positions shown (#1, 2, 3, 4) were extracted from
the 54 alpha URR sequences in the PaVE database that have the traditional four sites shown. URRs containing non-consensus E2 binding sites were not included. Sequence logos were
created for the E2 site at each position using Weblogo (http://weblogo.berkeley.edu/logo.cgi) (Crooks et al., 2004). (C) Number of E2 binding sites in the URRs of PV types in different
genera. The number of consensus (ACCN6GGT) E2 binding sites in the URR of PV types from genera of PVs with more than six members.
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Expression of the HPV8 E2 protein, but not HPV11 E2, in the
skin of transgenic mice results in the development of skin tumors
(Leykauf et al., 2008; Pfefferle et al., 2008). Furthermore, the
development of these tumors is accelerated by exposure to UV
radiation. The mechanism by which this occurs is still not under-
stood but several interesting hypotheses have been raised by
McLaughlin-Drubin and Munger (2008).
Regulation of cellular gene expression
E2 has been described to regulate the expression of cellular genes
in a few cases, but for the most part E2 has very little effect on cellular
transcription (Johung et al., 2007). This is probably because while there
are many E2 consensus sites in the host genome very few of them are
actually bound by E2 (Vosa et al., 2012) Furthermore, E2 does not
change the transcription of those that are bound (ibid.). A similar
ﬁnding was made by Jang et al. who showed that E2 (through aprotein–protein interaction with Brd4, not direct DNA binding) bound
to most active promoters in the host genome but this did not actually
change cellular gene expression (Jang et al., 2009). In contrast, a recent
study showed that when HPV16 E2 was expressed from the CMV
promoter in an adenovirus vector, hundreds of genes were upregu-
lated or downregulated (Ramirez-Salazar et al., 2011).
However, there are detailed studies examining the role of E2 in
regulating the expression of Matrix Metalloproteinase-9 (MMP-9)
(Akgul et al., 2006; Behren et al., 2005; Gasparian et al., 2007;
Muhlen et al., 2010), IL-10 (Bermudez-Morales et al., 2011), hTERT
(Lee et al., 2002b), beta 4-integrin (Oldak et al., 2010, 2004) and
the splicing factor SF2/ASF (Mole et al., 2009).
Domain structure of the E2 proteins
Transactivation domain
The amino-terminal 200 amino acids of the full-length E2
protein fold into a conserved structural domain. This crystal
L1 E6
ori
early promoter
1234
pAL
alpha HPV18
beta HPV8
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Fig. 7. Map of the E1 and E2 binding sites in the URR of Papillomaviruses from several genera. The URRS of PVs selected from nine different genera are shown. The ends of
the L1 and E6 ORFs are indicated. The E1 binding site, when mapped, is indicated by a blue box, while putative sites are indicated by purple boxes. E2 binding sites that
match the consensus ACCN6GGT are shown as cyan circles. E2 sites that deviate from this consensus are shown as light purple circles.
Fig. 8. Expression of E2 in a Bovine FibroPapilloma. Shown is a section of tissue from a BPV1 infected ﬁbropapilloma. Host cells are visualized in the left panel using DAPI to
stain nuclei. The E2 protein is detected in the right panel using a BPV1 E2 speciﬁc monoclonal antibody (B201) with an epitope between residues 160 and 200 in the E2
protein. B201 antiserum was a gift from Elliot Androphy (Yao et al., 1998).
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and HPV18 (Abbate et al., 2004; Antson et al., 2000; Harris and
Botchan, 1999; Sanders et al., 2007; Wang et al., 2004). Fig. 2A
shows the structures of this domain for BPV1, HPV11 and HPV16.
In all PVs, the transactivation domain forms cashew shaped
structure. As described by Antson et al. for HPV16, the N-
terminal half of the domain (N1: residues 1–91) is composed of
three long alpha helices folded anti-parallel to each other in a
bundle. The C-terminal half (N2: residues 110–201) is composed
mostly of anti-parallel beta-sheets. The region between N1 and N2
(residues 93–109) has been designated the “fulcrum” and consists
of a two-turn helix (Antson et al., 2000). The N-terminal domains
of other E2 proteins form almost identical structures (Abbate et al.,2004; Harris and Botchan, 1999; Sanders et al., 2007; Wang et al.,
2004). Residues within the E2 “transactivation” domain are impor-
tant for both transcriptional activation and repression, and repli-
cation. Residues important for transcriptional regulation (eg R37
and I73) are found on the outside, convex face of the domain.
Conversely, a residue important for replication and interaction
with the E1 protein (E39) is found on the concave face of the
structure.
The HPV16 E2 N-terminal domain can self-interact and in the
original structure was observed to dimerize through residues
important for transcriptional regulation (R37 and I73) (Antson
et al., 2000). This is consistent with several studies that show that
the E2 proteins can loop DNA containing widely spaced E2 binding
 transcription and chromatin processes
mRNA processing
protein transport
ubiquitin and ubiquitin like conjugation
pathway
cell cycle, chromsome structure and
partitioning
DNA replication and repair
apostosis
Fig. 9. Functional categories of E2 associated proteins. The E2 associated proteins shown in Table 2 were categorized according to Gene Ontology functions using the DAVID
v6.7 bioinformatics resource (Vempati, 2012) with some manual curation.
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Ramon et al., 2008; Knight et al., 1991; Sim et al., 2008). The crystal
structure of the BPV1 transactivation domain was also observed to
be dimeric but in this case dimerization was mediated through a
cysteine residue (C57) at the end of helix 2 (Sanders et al., 2007).
Disulﬁde formation of residue C57 between two N-terminal
domains promoted association of the two concave faces of the
structure, sequestering the region required for E1 association (see
below). This is the opposite face N-terminal domain found to
mediate self-association in the HPV16 structure. A mutational
analysis of the BPV1 dimerization interface determined that while
it might contribute to replication activity, it was not essential
(Gagnon et al., 2013). Lastly, the N-terminal domains of HPV11 E2
and the HPV18 E2 (in complex with E1) were observed to be
monomeric (Abbate et al., 2004; Wang et al., 2004). Therefore,
more studies are required to determine the signiﬁcance of the self-
association/looping function of the E2 proteins.
DNA binding and dimerization
The E2 protein is a sequence speciﬁc DNA binding protein that
binds to speciﬁc consensus motifs (ACCGN4CGGT or ACCN6GGT)
located mainly in the URR (Androphy et al., 1987; Hawley-Nelson
et al., 1988; Moskaluk and Bastia, 1987). A conserved C-terminal
domain (approximately 85–100 amino acids) comprises the DNA
binding domain (McBride et al., 1988; Moskaluk and Bastia, 1988).
The E2 protein also forms very stable dimers through the DNA
binding domain (Dostatni et al., 1988; McBride et al., 1989b;
Moskaluk and Bastia, 1989). The structure of the E2 binding
domain of BPV1 bound to its DNA target was solved in 1992 and
was revealed to form a novel dimeric, eight-stranded, anti-parallel
beta-barrel structure (Hegde et al., 1992). Two alpha helices on the
surface of the barrel comprise the DNA recognition surface and
amino acid residues on these helices are involved in speciﬁc base
recognition. Since the structure of the BPV DNA binding domain
was determined, there have been many additional structures
solved for the homologous domains of HPV6, 16, 18 and 31
(Bussiere et al., 1998; Hegde and Androphy, 1998; Hooley et al.,
2006; Kim et al., 2000; Nadra et al., 2004) and currently there are
15 different E2 DNA binding domain structures hosted on the PaVE
website. Fig. 2B shows the structure of the DNA binding domains
of HPV18, HPV6 and BPV1 domains. The domains of different PV
E2 proteins have a very similar structure overall, although there
are differences in the relative orientation of the two subunits
(reviewed in (Hegde, 2002)).
It should be noted that most structures are of the C-terminal 81
to 87 residues of E2. However, the C-terminal 100 residues are wellconserved and form a DNA binding domain that is more stable and
binds with up to eight-fold increased afﬁnity (McBride et al., 1988;
Pepinsky et al., 1997). A structure of the C-terminal 101 residues of
BPV1 E2 (PDB:1DBD) showed that the additional N-terminal
sequences form a ﬂap that covers a cavity in the dimer to augment
stability and DNA binding (Veeraraghavan et al., 1998).
The E2 DNA binding site is bent smoothly around the protein
domain to enable successive major grooves to interact with the
recognition helices (Hegde et al., 1992). Fig. 3A shows sequence
conservation logos of the E2 recognition helices from nine differ-
ent genera of papillomaviruses. There is remarkably high con-
servation in the speciﬁcity determining residues. In the Delta-PV
BPV1 E2, the recognition helix residues N4 (BPV N336), K7 (K339),
C8 (C340) and F11 (F343) make speciﬁc and base discriminatory
contacts with nucleotides on each half of the target sequence. R12
(R344) is hydrogen bonded through a water molecule with a
nucleotide just outside of the consensus. Fig. 3B shows these
speciﬁc contacts between residues in the recognition helix and the
consensus DNA binding site. Hegde predicted that G1 (G333 in
BPV) was essential for the sharp turn between beta strand 1 and
the recognition helix and that N4 (N336 in BPV) was essential for
“capping” the helix. Notably, these residues are absolutely con-
served in all PVs sequenced to date. E2 binds to different sequence
motifs with varying afﬁnity (Li et al., 1989) but the DNA contacts
are similar. Rather, binding afﬁnity correlates with the ﬂexibility of
the DNA target sequence (Kim et al., 2000). Furthermore, the
preference of different E2 proteins for ﬂexible or non-ﬂexible
targets correlates with positive charge on the DNA interaction
surface (Kim et al., 2000).
E2 forms a highly stable dimer (McBride et al., 1989b; Mok
et al., 1996; Moskaluk and Bastia, 1989) and the ﬁrst E2 structure
revealed why (Hegde et al., 1992). The interface between mono-
mers is extensive and dimerization buries between 1500 Å2 and
2500 Å2 of protein among the different E2 structures (reviewed in
(Hegde, 2002). This results in a large hydrophobic beta-barrel
containing numerous large and intricately packed side chains. The
stable dimer forms upon translation and there is no subsequent
mixing of the monomers without the use of strong denaturants
(McBride et al., 1989b). The hydrophobic core of the beta-barrel
contains a highly conserved tryptophan residue at position 360 (in
BPV1) that has been named the tryptophan bridge (Corina et al.,
1993; Prakash et al., 1992). The indole rings of the tryptophan from
each subunit are in Van der Waals contact which allows them to
be crosslinked by UV irradiation (Prakash et al., 1992). Mutated
BPV1 E2 proteins containing substitutions of hydrophobic residues
at this position are functional but substitution with polar residues
disrupts dimerization (see Fig. 11a).
A.A. McBride / Virology 445 (2013) 57–7966Remarkably, the E2 DNA binding domain has great structural
similarity with that of the EBV EBNA1 protein, despite no sequence
similarity (Bochkarev et al., 1995). The DNA binding domain of the
KSHV LANA protein likely also has the same fold (Grundhoff and
Ganem, 2003).
Hinge region
The hinge region of the E2 protein is encoded by a variable
region of the PV genomes that overlaps the E4 ORF. It is not well
conserved and is variable both in sequence composition and in
length (Giri and Yaniv, 1988; McBride et al., 1989b). As shown in
Fig. 4, the length of the hinge is very variable between the E2s of
different PV genera, but quite similar within each genus. Corre-
spondingly, the length of the E4 proteins also varies considerably
between genera. Narechania et al. have shown that purifying
selection of the overlapping E4 ORF gives rise to a disproportionate
amount of non-synonymous change in the E2 hinge (Narechania
et al., 2005).
The E2 hinge is thought to be unstructured and to form a
ﬂexible link between the transactivation and DNA binding
domains (Gauthier et al., 1991). Most E2 hinges are rich in proline,
serine, threonine, glycine and arginine residues. The hinge is not
required for the basic transcriptional and replication functions of
E2, though some spacing is required to avoid steric hindrance
between the domains (Winokur and McBride, 1992). Nevertheless,
the E2 hinge regions from each genus of PVs encode auxiliary
functions such as the determinants for intracellular localization,
chromatin binding and protein stability. These functions are often
regulated by phosphorylation. For example, a short sequence in
the BPV1 hinge, next to the DNA binding domain, comprises a
phosphorylation-dependent conformational switch (Garcia-AlaiE2
E1
E39
R454
Fig. 10. Structure of an E1–E2 complex. The structure of the HPV18 E2 transactiva-
tion domain in complex with a C-terminal fragment of E1 (residues 428–631) was
rendered in Pymol (PDB: 1TUE). Highlighted on the structure in red is E39, which
forms a buried salt bridge with the highly conserved residue arginine 454 in E1
(shown in orange).et al., 2006; McBride et al., 1989a; Penrose et al., 2004). Phosphor-
ylation of this region by CK2 induces proteasomal degradation of
the E2 and modulates genome copy number (McBride and Howley,
1991; Penrose and McBride, 2000). This sequence is conserved
among Delta-PVs. In the Beta-PVs, a highly conserved RXXS motif
in the E2 hinge is phosphorylated by PKA. This promotes binding
to host chromatin and mitotic chromosomes and stabilizes the E2
protein (Sekhar and McBride, 2012; Sekhar et al., 2010). In the
alpha-PVs, a highly conserved KRXR motif promotes nuclear
localization and association of the E2 proteins with the nuclear
matrix (Zou et al., 2000).The Beta-PV E2 hinges are rich in serine–
arginine dipeptides and this promotes the localization of these
proteins with cellular splicing speckles and their association with
splicing proteins (Lai et al., 1999; Sekhar et al., 2010). The hinge
region of many E2 proteins also interacts with cellular proteins
(see Table 2).
E84E2
All PVs have the capacity to encode an E84E2 repressor protein
consisting of a short E8 peptide fused to the entire hinge and DNA
binding domains of E2. The E84E2 proteins are powerful repres-
sors of viral transcription and replication (Jeckel et al., 2003;
Stubenrauch et al., 2007; Stubenrauch et al., 2001; Zobel et al.,
2003). The E8 moiety is just 11–13 amino acids, yet it has powerful
repressor properties. In the Alpha-E2 proteins, a KWK motif is
important for the repressor function (Stubenrauch et al., 2001;
Zobel et al., 2003). Sequence alignments of a selection of Alpha-PV,
and all Lambda and Delta-PV E8 domains are shown in Fig. 5. Each
E8 domain is rich in basic and hydrophobic residues. Table 2
contains cellular proteins that associate with E84E2.E2 binding sites in papillomavirus genomes
The consensus E2 binding site
The consensus E2 DNA binding motif was ﬁrst determined for
BPV1 E2 using a DNA protein immunoprecipitation assay
(Androphy et al., 1987; Hawley-Nelson et al., 1988). The consensus
is ACC(N)6GGT, or more stringently ACCG(N)4CGGT. Further studies
using DNase I footprinting and mobility shift assays showed that
there are actually 17 E2 binding sites in the BPV1 genome, only 12
of which match the consensus. The non-consensus sequences are
AACN6GGT or AACN6GTT (Li et al., 1989). Furthermore, the E2
protein binds to these 17 sites with afﬁnities that ranges over 300
fold (Li et al., 1989). The number of spacer (N) nucleotides is
always invariant, but Alpha-E2 proteins bind more readily to sites
with an AT rich spacer, while there is no apparent preference for
BPV1 E2 (Hegde, 2002).
Fig. 6A shows sequence conservation logos for the E2 binding
consensus sequences (ACC(N)6GGT) from nine different genera of
papillomaviruses. The predilection for the complete ACCG
(N)4CGGT is apparent in all PVs, and the previously described
preference of the alpha-PVs for an A/T rich spacer region is clear.
The alpha-PV genomes most often contain four E2 binding sites
located at speciﬁc positions within the URR. Fig. 6B shows the
position and sequence conservation of the individual binding sites.
Binding sites 1 and 2 are located in the early promoter region. The
origin (and E1 binding site) is located just upstream from the
promoter and the binding sites ﬂanking the E1 binding site are
required for optimal origin activity. Binding site 4 is located about
300–400 nucleotides upstream.
When the conservation of the spacer nucleotides is considered
individually for each binding site, it becomes clear that Alpha-PV
E2 binding sites 1 and 2 have primarily A nucleotides on the sense
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Fig. 11. Landmarks and mutations in the E2 DNA binding domain. (A) Key residues on the DNA binding domain. The BPV1 E2 DNA binding domain structure PDB: 1DBD was
rendered in Pymol. Highlighted on the structure are regions of interest. In red is the region in BPV1 E2 that interacts with E1 when both proteins are bound to adjacent sites
(Gillitzer et al., 2000). The same helix interacts with p53, and shown in orange on the other monomer are residues that when mutated (HPV16 D338, E340, W341, D344)
reduce p53 binding (Brown et al., 2008). Also indicated are potential SUMO modiﬁcation sites (gray) and cdk2 phosphorylation sites (yellow) (Johansson et al., 2009; Wu
et al., 2008). In cyan are two tryptophan residues that are readily crosslinked in the dimer by UV radiation (Corina et al., 1993). These sites have been mapped in different
E2 proteins and are shown on the BPV1 domain for illustrative purposes only. (B) Mutational analysis of the E2 recognition helix. The phenotype of the amino acid
substitutions shown are divided into three categories according to their ability to speciﬁcally bind DNA. Mutations shown in black are from BPV1 (Carruth and McBride,
2001; Grossel et al., 1996; McBride et al., 1992; Prakash et al., 1992; Ustav et al., 1993). Mutations shown in light blue are from HPV11 (Matsumoto et al., 1997).
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does not seem to be strong preference for binding site 3. This
implies that the orientation of each binding site might be impor-
tant for function. In several cases the E2 binding sites overlap with
the binding site for a cellular factor and this could inﬂuence the
sequence of individual E2 sites independent from E2 binding
(Jackson and Campo, 1995; May et al., 1991, 1994; Schmidt et al.,
1997; Stenlund and Botchan, 1990; Vande Pol and Howley, 1990).
More extensive analyses of E2 binding sites can be found in studies
by Sanchez et al. and Rogers et al. (Rogers et al., 2011; Sanchez
et al., 2007).
Notably, most E2 binding sites contain at least one CpG
dinucleotide. Methylation of the cytosine in CpG motifs is one of
the major epigenetic modiﬁcations in mammalian cells and
strongly correlates with transcriptional repression. Methylation
of the E2 binding site disrupts E2 binding and the ability of E2 to
regulate transcription (Kim et al., 2003; Thain et al., 1996). Viral
DNA is methylated in clinical isolates and methylation of E2 sites
that mediate repression of the early promoter could promote
oncogenesis (Kalantari et al., 2004, 2008). In general, viral DNA
that is actively replicating and transcribing (especially during
differentiation) is unmethylated, and integrated DNA or untran-
scribed regions (such as the late region in cancers) are methylated
(Turan et al., 2006). However, there is some controversy about the
differential methylation of individual E2 binding sites in different
viral states (reviewed in (Chaiwongkot et al., 2013)). It is clear that
there is evolutionary pressure to maintain a CpG dinucleotide
within an E2 binding site, even although this gives the host cell the
ability to regulate viral functions. The presence of the CpG
dinucleotide must be advantageous to the viral life cycle for the
virus to relinquish this control. For example, DNA methylation is
regulated during keratinocyte differentiation and is important
for nucleosome positioning and destabilization (reviewed in
(Chatterjee and Vinson, 2012), which could add another level of
regulation to HPV gene expression.
Distribution of E2 sites in the URR of different papillomavirus genera
The genomes of some papillomaviruses viruses contain only a
few E2 binding motifs, while others have many more (see Fig. 6C).
The number and position of the sites are relatively well conservedamong viruses from the same genera. Fig. 7 shows the distribution
of E2 binding sites in the URR of a selection of papillomaviruses
whose genus contains at least six types. For example, most Alpha-
PVs contain four consensus E2 binding sites with conserved
spacing, as shown in Fig. 6B. These sites are important for
transcriptional activation and repression, initiation of replication
and for viral genome partitioning and maintenance.
The origin of replication is usually located at the 3′ end of the
URR and consists of an E1 binding site, an AT rich region and one
or more E2 binding sites (Mohr et al., 1990; Ustav et al., 1993;
Ustav et al., 1991). E1 binds to an 18bp palindrome that contains
multiple overlapping hexanucleotide E1 recognition sequences
(Auster and Joshua-Tor, 2004), but this sequence is not highly
conserved in all PVs (reviewed in (McBride, 2008). E2 binds to
adjacent sites to assist in loading the E1 helicase onto the origin
(Mohr et al., 1990). E1 and E2 bind cooperatively as dimers to
adjacent sites in the origin but in the presence of ATP, E1 converts
to a hexamer and E2 is displaced (Sanders and Stenlund, 1998). E2
can load E1 to the origin when the E1 and E2 sites are proximal,
but also from a distance. In the latter case, E2 displacement is not
required (Sanders and Stenlund, 2001).
Seventeen E2 binding sites have been mapped in the Delta-PV
BPV1 and 11 of these are located in the URR (Li et al., 1989). At
least eight of these URR E2 binding sites are required for genome
maintenance and these have been mapped to an element called
the Minichromosome Maintenance Element or MME (Piirsoo et al.,
1996). Many papillomaviruses do not have eight E2 binding sites
and so there must be differences in the requirements for genome
maintenance between different viral types. It is difﬁcult to inter-
pret the phenotype of viruses with mutations in the E2 binding
sites in the background of the entire viral genome, because E2 is
important for so many key processes in the viral life cycle.
However, while the speciﬁc arrangement of E2 binding sites is
important, at least one site (HPV31 site #3) is dispensable for
stable genome maintenance (Stubenrauch et al., 1998b).
Although BPV1 has 17 E2 binding sites, only 12 match the
ACCN6GGT consensus. Therefore, it is likely that other PVs contain
additional E2 binding sites. Alignment of the URRs from viruses
within a speciﬁc genus shows that there is very likely to be
additional conserved, non-consensus E2 binding sites. Further-
more, many viruses have a few E2 binding sites in the coding
Table 2
E2 associated proteins validated by functional or biochemical analyses
Domains HPV Type Gene
Symbol
Synonyms UniProt Protein Name Reference
E2 HPV11 16 18 AR Uniprot: P10275 Androgen receptor (Wu et al., 2007a)
C HPV18 BRCA1 Uniprot: P38398 Breast cancer type 1 susceptibility protein (Kim et al., 2003)
N BPV1 BRD4 Uniprot: O60885 Bromodomain-containing protein 4 (Baxter et al., 2005)
E2 BPV1 AaPV1 CPV1 SfPV1 OcPV1
OvPV1
HPV 1 4 11 16 31 57
BRD4 Uniprot: O60885 Bromodomain-containing protein 4 (McPhillips et al., 2006)
N HPV16 BRD4 Uniprot: O60885 Bromodomain-containing protein 4 (Schweiger et al., 2006)
N SfPV1 HPV 11 31 BRD4 Uniprot: O60885 Bromodomain-containing protein 4 (Senechal et al., 2007)
E2 BPV1 HPV16 BRD4 Uniprot: O60885 Bromodomain-containing protein 4 (Smith et al., 2010)
NC HPV5 BRD4 Uniprot: O60885 Bromodomain-containing protein 4 (Wang et al., 2009a)
N HPV11 BRD4 Uniprot: O60885 Bromodomain-containing protein 4 (Wu et al., 2006)
N BPV1 HPV16 BRD4 Uniprot: O60885 Bromodomain-containing protein 4 (You et al., 2004)
H HPV5 C1QBP Uniprot: Q07021 Complement component 1 Q subcomponent-binding protein, mitochondrial (Lai et al., 1999)
N HPV18 CASP8 FLICE Uniprot: Q14790 Caspase-8 (Thierry and Demeret, 2008)
N HPV16 18 CDC20 Uniprot: Q12834 Cell division cycle protein 20 homolog (Bellanger et al., 2005)
C BPV1 HPV8 16 18 CEBPA Uniprot: P49715 CCAAT/enhancer-binding protein alpha (Hadaschik et al., 2003)
C BPV1 HPV8 16 18 CEBPB Uniprot: P17676 CCAAT/enhancer-binding protein alpha (C/EBP alpha) (Hadaschik et al., 2003)
E2 HPV16 CFLAR cFLIP Uniprot: O15519 CASP8 and FADD-like apoptosis regulator (Wang et al., 2011)
E8^E2 HPV31 CHD6 Uniprot: Q8TD26 Chromodomain-helicase-DNA-binding protein 6 (Fertey et al., 2010)
E2 HPV 9 CLTA Uniprot: P09496 Clathrin light chain A (Muller et al., 2012)
E2 HPV16 CPSF4 CPSF30 Uniprot: O95639 Cleavage and polyadenylation speciﬁcity factor subunit 4 (Johansson et al., 2012)
N HPV18 CREBBP CBP Uniprot: Q92793 CREB-binding protein (Lee et al., 2000)
E2 BPV1 CUL3 Uniprot: Q13618 Cullin-3 (Zheng et al., 2009)
N BPV1 HPV 11 16 DDX11 CHLR1 Uniprot: Q96FC9 Probable ATP-dependent RNA helicase DDX11 (Parish et al., 2006a)
N H C BPV1 HPV 8 18 EP300 p300 Uniprot: Q09472 Histone acetyltransferase p300 (Muller et al., 2002)
E2 BPV1 EP300 p300 Uniprot: Q09472 Histone acetyltransferase p300 (Peng et al., 2000)
E2 BPV1 HPV16 EP400 P400 Uniprot: Q96L91 E1A-binding protein p400 (Smith et al., 2010)
N HPV16 8 FZR1 CDH1 Uniprot:
Q9UM11
Fizzy-related protein homolog (Bellanger et al., 2005)
N BPV1 GPS2 AMF1 Uniprot: Q13227 G protein pathway suppressor 2 (Breiding et al., 1997)
E2 BPV1 GPS2 AMF-1 Uniprot: Q13227 G protein pathway suppressor 2 (Peng et al., 2000)
E2 HPV11 16 18 GRIP1 Uniprot: Q9Y3R0 Glutamate receptor-interacting protein 1 (Wu et al., 2007b)
E2 HPV 16 GTF2B Uniprot: Q00403 Transcription initiation factor IIB (Muller et al., 2012)
E8^E2 HPV31 HDAC1 Uniprot: Q13547 Histone deacetylase 1 (Ammermann et al., 2008)
E8^E2 HPV31 HDAC2 Uniprot: Q92769 Histone deacetylase 2 (Ammermann et al., 2008)
E8^E2 HPV31 HDAC3 Uniprot: O15379 Histone deacetylase 3 (Ammermann et al., 2008)
E8^E2 HPV31 HDAC3 Uniprot: O15379 Histone deacetylase 3 (Powell et al., 2010)
NH C HPV18 KAT2B PCAF Uniprot: Q92831 Histone acetyltransferase KAT2B (Lee et al., 2002a)
E2 BPV1 HPV16 KDM5C JARID1C,
SMCX,
Uniprot: P41229 Lysine-speciﬁc demethylase 5C (Smith et al., 2010)
E2 HPV1 3 5 6 8 9 16 18 KIF20A Uniprot: O95235 Kinesin-like protein KIF20A (Muller et al., 2012)
N BPV1 HPV16 11 KIF20A Uniprot: O95235 Kinesin-like protein KIF20A (Yu et al., 2007)
E2 BPV1 HPV11 16 KPNA3 Uniprot: O00505 Importin subunit alpha-3 (Bian and Wilson, 2010)
E2 BPV1 HPV11 16 KPNA5 Uniprot: O15131 Importin subunit alpha-6 (Bian and Wilson, 2010)
C HPV16 MDM2 Uniprot: Q00987 E3 ubiquitin-protein ligase Mdm2 (Gammoh et al., 2009)
N BPV1 HPV8 18 NAP1L1 NAP1 Uniprot: P55209 Nucleosome assembly protein 1-like 1 (Rehtanz et al., 2004)
E8^E2 HPV31 NcoR Uniprot: O75376 Nuclear receptor corepressor 1 (Powell et al., 2010)
N HPV16 NRIP Uniprot: P48552 Nuclear receptor-interacting protein 1 (Chang et al., 2012)
C HPV18 PARP1 Uniprot: P09874 Poly [ADP-ribose] polymerase 1 (Lee et al., 2002b)
E2 HPV11 16 18 PLAL1 ZacI Uniprot:
Q9UM63
Zinc ﬁnger protein PLAGL1 (Wu et al., 2007b)
N HPV5 PLK1 Uniprot: P53350 Serine/threonine-protein kinase PLK1 (Wang et al., 2009a)
E2 BPV1 RPA1 RPA-70 Uniprot: P27694 Replication protein A 70 kDa DNA-binding subunit (Li and Botchan, 1993)
E8^E2 HPV31 SETDB1 Uniprot: Q15047 Histone-lysine N-methyltransferase SETDB1 (Ammermann et al., 2008)
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H HPV5 SFRS1 ASF, SF2,
SFRS1
Uniprot: Q07955 Serine/arginine-rich splicing factor 1 (Lai et al., 1999)
H HPV5 SFRS2 SC35 Uniprot: Q01130 Serine/arginine-rich splicing factor 2 (Lai et al., 1999)
H HPV5 SFRS7 Uniprot: Q16629 Serine/arginine-rich splicing factor 7 (Lai et al., 1999)
N HPV18 SKP2 Uniprot: Q13309 S-phase kinase-associated protein 2 (Bellanger et al., 2010)
N BPV1 SMARCA2 BRM Uniprot: P51531 Probable global transcription activator SNF2L2 (Kumar et al., 2007)
E2 HPV 18 SMARCA4 Brg1 Uniprot: P51532 Transcription activator BRG1 (Cha and Seo, 2011)
N C HPV6 11 16 18 SMARCB1 hSNF5 Uniprot: Q12824 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B
member 1
(Cha and Seo, 2011)
N HPV11 SMC5 Uniprot: Q8IY18 Structural maintenance of chromosomes protein 5 (Wu et al., 2006)
N HPV11 SMC6 Uniprot: Q96SB8 Structural maintenance of chromosomes protein 6 (Wu et al., 2006)
N BPV1 HPV11 16 18 SMN1 Uniprot: Q16637 Survival motor neuron protein (Strasswimmer et al., 1999)
H HPV5 SNRNP70 Uniprot: P08621 U1 small nuclear ribonucleoprotein 70 kDa (Lai et al., 1999)
N C BPV1 HPV18 SP1 Uniprot: P08047 Transcription factor Sp1 (Steger et al., 2002)
H C HPV18 8 SP1 Uniprot: P08047 Transcription factor Sp1 (Steger et al., 2002)
C HPV16 SRSF1 ASF SF2 Uniprot: Q07955 Serine/arginine-rich splicing factor 1 (Bodaghi et al., 2009)
C HPV16 SRSF4 Uniprot: Q08170 Serine/arginine-rich splicing factor 4 (Bodaghi et al., 2009)
C HPV16 SRSF5 Uniprot: Q13243 Serine/arginine-rich splicing factor 5 (Bodaghi et al., 2009)
N C BPV1 HPV18 TAF1 TAFII250 Uniprot: P21675 Transcription initiation factor TFIID subunit 1 (Carrillo et al., 2004)
N C HPV16 TAF1 TAFII250 Uniprot: P21675 Transcription initiation factor TFIID subunit 1 (Centeno et al., 2008)
N C BPV1 HPV18 TAF6 TAFII80 Uniprot: P49848 Transcription initiation factor TFIID subunit 6 (Carrillo et al., 2004)
H C HPV 8 TAF7 TAFII55 Uniprot: Q15545 Transcription initiation factor TFIID subunit 7 (Enzenauer et al., 1998)
N BPV1 HPV16 18 TAX1BP1 Uniprot: Q86VP1 Tax1-binding protein 1 (Wang et al., 2009b)
N C BPV1 HPV18 TBP Uniprot: P20226 TATA-box-binding protein (Carrillo et al., 2004)
C HPV 8 TBP Uniprot: P20226 TATA-box-binding protein (Enzenauer et al., 1998)
E2 HPV11 TBP Uniprot: P20226 TATA-box-binding protein (Hartley and Alexander,
2002)
C BPV1 TBP Uniprot: P20226 TATA-box-binding protein (Rank and Lambert, 1995)
N HPV16 TFIIB Uniprot: Q00403 Transcription initiation factor IIB (Benson et al., 1997)
C BPV1 TFIIB Uniprot: Q00403 Transcription initiation factor IIB (Rank and Lambert, 1995)
N BPV1 TFIIB Uniprot: Q00403 Transcription initiation factor IIB (Yao et al., 1998)
H HPV5 TNPO3 Uniprot: Q9Y5L0 Transportin-3 (Lai et al., 1999)
E2 HPV11 TOP1 TopoI Uniprot: P11387 DNA topoisomerase 1 (Clower et al., 2006)
N HPV16 TOPBP1 Uniprot: Q92547 DNA topoisomerase 2-binding protein 1 (Boner et al., 2002)
C HPV16 TP53 p53 Uniprot: P04637 Cellular tumor antigen p53 (Massimi et al., 1999)
C HPV 6 11 16 TP53 p53 Uniprot: P04637 Cellular tumor antigen p53 (Parish et al., 2006b)
H HPV5 TRA2B Uniprot: P62995 Transformer-2 protein homolog beta (Lai et al., 1999)
E8^E2 HPV31 TRIM28 Uniprot: Q13263 Transcription intermediary factor 1-beta (Ammermann et al., 2008)
E2 BPV1 HPV16 UBE2I UBC9 Uniprot: P63279 SUMO-conjugating enzyme UBC9 (Wu et al., 2008)
E2 HPV 1 3 5 8 9 11 18 VPS39 Uniprot: Q96JC1 Vam6/Vps39-like protein (Muller et al., 2012)
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A.A. McBride / Virology 445 (2013) 57–7970regions of the genome, although most are located in the URR.
Further studies are required to determine why some viruses have
so few apparent E2 binding sites while others have many more
and whether the E2 binding sites in the coding regions have any
signiﬁcance. Fig. 6C shows the numbers of consensus E2 binding
sites found in the URR of nine different genera of PVs.E2 protein post-translational modiﬁcations
Phosphorylation
The E2 proteins from BPV1, HPV8, HPV16 and SfPV1 have been
shown to be phosphorylated and it is likely that all E2 proteins share
this modiﬁcation (Barbosa and Wettstein, 1988; Chang et al., 2011;
Johansson et al., 2009; Lehman et al., 1997; McBride et al., 1989a;
Sanders et al., 1995; Sekhar and McBride, 2012; Sekhar et al., 2010).
BPV1 E2 contains phosphoserine, plus a small amount of
phosphothreonine (McBride et al., 1989a). The major phosphor-
ylation sites in vivo have been mapped by biochemical and genetic
analyses to serine residues 298 and 301 (McBride et al., 1989a). An
additional minor phosphorylation site was detected at E2 residue
235 by mass spectroscopy (Lehman et al., 1997). It should be noted
that in the cloned BPV genome this E2 residue is a serine but in
cloned E2 cDNAs (Baker et al., 1987) prepared from wart RNA it is
an alanine, indicating that it may be a variant residue (AMcB,
unpublished data). The two major phosphorylation sites (298 and
301) are located in the hinge region of E2, just outside the DNA
binding domain and they are conserved in all Delta-PV E2
proteins. Phosphorylation of these residues by CK2, induces the
proteasomal degradation of E2 and so phosphorylation regulates
E2 stability and viral genome copy number (McBride and Howley,
1991; Penrose et al., 2004; Penrose and McBride, 2000).
In HPV16, a putative threonine phosphorylation site at amino
acid 286 can be phosphorylated in vitro by Cdk2 (Johansson et al.,
2009). This phosphorylation site is conserved in 36 of the 76
Alpha-PVs currently in the PaVE database and examination of this
residue in the homologous HPV31 structure 1DHM shows that this
residue is on the surface of the DNA binding domain, where the
hinge meets the C-terminal domain (see Fig. 11A). This is in a
similar position to the BPV phosphorylation sites (see Fig. 4).
The hinge of the HPV8 E2 protein is highly phosphorylated in vivo
(Sekhar and McBride, 2012; Sekhar et al., 2010). Much of this
phosphorylation probably occurs on the many SR motifs located in
the hinge. Furthermore, we ﬁnd that the SR protein kinases, SRPK1
and 2, are associated with HPV8 E2 (Jang and McBride, 2013). The
hinge of HPV E2 contains a short peptide that mediates tethering to
host chromatin and mitotic chromosomes (Sekhar et al., 2010). This
peptide contains an RXXS motif (residues 250–253) that is conserved
in all Beta-PV E2 proteins. Serine 253 is phosphorylated by PKA in S-
phase and this stabilizes E2 and promotes binding of E2 to host
chromatin (Sekhar and McBride, 2012).
Acetylation
Diverse E2 proteins (BPV1, HPV8 and HPV16) interact with the
cellular lysine acetyl transferases, p300, CBP and pCAF and this
enhances E2-mediated transcriptional activation (Kruppel et al.,
2008; Lee et al., 2002a, 2000; Muller et al., 2002; Peng et al.,
2000). Quinlan et al. have shown that p300 can acetylate BPV1 E2
in vitro on two highly conserved lysine residues (Quinlan et al.,
2013). These residues (K111 and 112) are highly conserved in all PV
E2 proteins and every PV E2 protein has at least one lysine in this
position. Lysines 111 and 112 are located in the fulcrum of the
transactivation domain, in a region previously shown to modulate
nuclear localization of E2 (Abroi et al., 1996; Skiadopoulos andMcBride, 1996). Quinlan et al. conﬁrm that these residues are
required for nuclear retention and show that p300 and CBP
promote nuclear localization of wildtype E2 (Quinlan et al., 2013).
Sumoylation
The SUMO conjugation enzyme, Ubc9, binds to and sumoylates
the BPV1 and HPV16 E2 in vitro (Wu et al., 2008). The consensus
motif for sumoylation is the lysine in the consensus motif ΨKx(E/
D), where Ψ is a bulky hydrophobic residue. The SUMOylation site
in HPV16 E2 is K292, which is just one residue before the highly
conserved glycine that makes the turn into the DNA recognition
helix (see Fig. 11A). This residue is conserved in 46 out of the 76
Alpha-PV E2 proteins currently in the PaVE database. Substitution
of K292 with an arginine does not affect the in vitro DNA binding
activity of E2 but it does reduce E2-mediated transcriptional
regulation (Wu et al., 2008). Increased sumoylation stabilizes E2
proteins from HPV11, HPV16 and HPV18 and this correlates well
with the concomitant increase in sumoylation (Deyrieux et al.,
2007; Wu et al., 2009) and E2 protein levels that occurs in
keratinocyte differentiation (see Section 7.1 and Fig. 8).
Redox regulation
The DNA recognition motif of all E2 proteins contains a highly
conserved cysteine residue that makes three direct contacts with
each half of the recognition site (see Figs. 3A, 3B 11A and B). The
basic environment surrounding the cysteine residue makes it
highly susceptible to oxidation, most likely to sulfenic acid
(McBride et al., 1992). The epithelium is under a redox gradient,
becoming more oxidizing at the superﬁcial layers (Korkina and
Pastore, 2009), and this is important for the maturation of HPV
virions (Conway et al., 2009). Thus, E2 DNA binding could be
modulated by the cellular environment during differentiation.
Mutation of this cysteine has modest effects on DNA binding
(depending on the substitution) and replication, but eliminates
E2's transcriptional functions (Grossel et al., 1996; McBride et al.,
1992).Localization
Intracellular localization
Both full-length and shorter E2 proteins localize primarily to the
nucleus (Hubbert et al., 1988), where they are observed in a nucleolar
excluded pattern (Burnett et al., 1990; Sekine et al., 1989; Skiadopoulos
and McBride, 1996; Zou et al., 2000). However, there is one report on
nuclear-cytoplasmic shuttling of high risk E2 proteins (Blachon et al.,
2005). Nuclear localization signals (NLS) have been mapped in BPV1,
HPV11 and HPV16 (Klucevsek et al., 2007; Skiadopoulos and McBride,
1996; Zou et al., 2000) and alpha importins 3 and 5 bind speciﬁcally to
these proteins (Bian and Wilson, 2010). In BPV1 there are two
potential NLSs. One is the recognition helix in the DNA binding
domain and this ﬁts the criteria of a classical NLS in that it is required
for nuclear localization and is transplantable to another protein
(Skiadopoulos and McBride, 1996). In vitro studies conﬁrm that this
region is also the NLS for HPV16 E2 (Klucevsek et al., 2007). The
second putative BPV1 NLS, PKRCFKKGARV, is in the fulcrum of the
transactivation domain and contains two highly conserved lysine
residues (111, 112). Proteins deleted of residues 101–110, or 111–120
are retained in the cytoplasm, but this sequence is not
transplantable (Skiadopoulos and McBride, 1996). The substitutions
K111A or K112A result in a cytoplasmic E2 protein (Abroi et al., 1996). It
is possible that this region is structurally sensitive and that deletions
here result in an unfolded protein that cannot be transported to the
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sensitive for transcription, replication and chromosome binding
(Zheng et al., 2005). Further studies showed that K111 and K112 are
acetylated and are important for nuclear retention of BPV1 E2
(Quinlan et al., 2013). In HPV11 a conserved patch of basic residues
in the hinge region (238–242) is important for both nuclear and
nuclear matrix localization (Zou et al., 2000).
The beta-PV E2 proteins have an additional sub-nuclear localiza-
tion to the SR-rich splicing speckles (Lai et al., 1999; Sekhar et al.,
2010). This interaction is mediated by SR rich sequences in the hinge
region of the Beta-E2 proteins. When HPV16 or HPV18 E2 are co-
expressed with E6 and E6nI proteins, E2 and E6 are found localized to
SR rich splicing speckles (Grm et al., 2005). In the absence of E6nI, E2
and E6 colocalize at ND10 domains (Grm et al., 2005).
As discussed above, E2 proteins also bind tightly to host
chromatin (Donaldson et al., 2007; Jang et al., 2009; Johansson
et al., 2009; Kurg et al., 2005; McPhillips et al., 2005; Sekhar and
McBride, 2012), the nuclear matrix (Zou et al., 2000) and mitotic
chromosomes (Ilves et al., 1999; Lehman and Botchan, 1998;
Oliveira et al., 2006; Skiadopoulos and McBride, 1998).
In the presence of the E1 protein, E1 and E2 form nuclear foci
that represent viral replication factories (Fradet-Turcotte et al.,
2011; Reinson et al., 2013; Sakakibara et al., 2011; Swindle et al.,
1999). In the presence of the L2 minor capsid protein, the E2
protein is recruited to ND10 domains in the nucleus and this is
thought to be important for establishment of viral infection (Day
et al., 2004; Day et al., 1998). However, ND10 domains are also
found adjacent to HPV replication foci (Swindle et al., 1999)
implying additional roles of these nuclear bodies in the HPV
lifecycle.
Tissue expression
The E2 proteins are easily detected in BPV1 infected wart
tissue. In this tissue, E2 can be detected at low levels along the
stratum basale and then at very high levels in a subset of cells in
the stratum spinosum. These cells are also vegetatively amplifying
the viral genome, indicating that E2 has an important role at this
stage of infection (Burnett et al., 1990; Penrose and McBride,
2000). An example of BPV1 E2 expression in bovine wart tissue
is shown in Fig. 8. The antibodies used in these studies detect both
full-length and repressor forms of E2, so it is difﬁcult to conclude
which forms of E2 are present in each cell layer. An antibody
against HPV6 E2 stained the nuclei in the middle and upper layers
of condyloma acuminata and laryngeal papillomas (Sekine et al.,
1989). Antibodies to HPV16 E2 have also detected E2 expression in
clinical tissue (Maitland et al., 1998; Xue et al., 2010). These studies
found that E2 was expressed in the intermediate and upper layers
of cervical CIN and koilocytic lesions. These studies all imply a role
for E2 in late stages of infection.E2 stability and degradation
The E2 proteins have a short half-life and this is regulated by
multiple factors. Full length BPV1 E2 has a half-life of 40 min and
the shorter repressor proteins E2-TR and E84E2 have half-lives of
10 min and 15 min, respectively (Hubbert et al., 1988). The
N-terminal domain is a target for proteasomal degradation
(Bellanger et al., 2001) and many E2 proteins can be stabilized
by association of this domain with a cellular protein. For example,
binding of Brd4 to the N-terminal domain of many E2 proteins
results in E2 stabilization (Gagnon et al., 2009; Lee and Chiang,
2009; Zheng et al., 2009). Brd4 prevents association of the E3
ubiquitin ligase, cullin-3, with E2 (Zheng et al., 2009). The
transactivation domain of HPV18 also binds the Skp1/Cullin1/F-box Skp2 (SCF(Skp2)) ubiquitin ligase in a Brd4-independent
manner resulting in the speciﬁc degradation of E2 at the end of
the G1 phase of the cell cycle (Bellanger et al., 2010). Tax1BP1 also
binds to the N-terminus of E2, preventing its proteasomal degra-
dation (Wang et al., 2009).
Interaction of E2 with other viral proteins can also affect stability.
The well-studied interaction between E2 and the E1 replication
protein can increase E2 stability (King et al., 2011), as can the
interaction of E2 with the late protein E14E4 (Davy et al., 2009).
The stability of E2 proteins can be modulated by phosphoryla-
tion. BPV1 E2 is phosphorylated by CK2 on residue 301 and this
promotes a conformational switch and proteasomal degradation
(McBride et al., 1989a; Penrose et al., 2004; Penrose and McBride,
2000). HPV16 E2 binds the nuclear receptor interaction protein
(NRIP), which recruits calcium and calmodulin thus activating the
phosphatase calcineurin to dephosphorylate E2, decrease E2
ubiquitination and increase E2 protein stability (Chang et al.,
2011). HPV8 E2 is phosphorylated on residue 253 by PKA and this
promotes binding to host chromatin and increased protein stabi-
lity (Sekhar and McBride, 2012). Both HPV8 and HPV16 E2 become
phosphorylated and stabilized in S-phase (Johansson et al., 2009;
Sekhar and McBride, 2012).
UVB irradiation decreases E2 stability (Taylor et al., 2003) and
sumoylation stabilizes E2, though not through direct sumoylation
of E2 (Wu et al., 2009) Notably, sumoylation increases with
keratinocyte differentiation and could contribute to E2 stabiliza-
tion at later stages of infection (Deyrieux et al., 2007).E2 associated proteins
Cellular proteins
E2 is a multifunctional protein that operates by binding to the
viral genome and recruiting a multitude of cellular proteins
required for each function of E2. Table 2 lists E2 associated
proteins that have been validated by either functional or biochem-
ical means. These proteins fall into several categories that include
transcriptional regulation, RNA processing, apoptosis, cell cycle,
nuclear import and protein degradation (see Fig. 9). A discussion
on the role of each of these protein interactions is beyond the
scope of this chapter and readers are directed to comprehensive
reviews on the E2-host protein network (Muller and Demeret,
2012), the role of E2 in tumorigenesis (Bellanger et al., 2011), in
viral DNA replication (McBride, 2008), in RNA processing
(Johansson and Schwartz, 2013), in genome tethering (McBride
et al., 2012) and the role of Brd4 in PV infection (McBride and Jang,
2013). Supplementary Table 1 lists many more E2 associated
proteins that have been identiﬁed by yeast two hybrid or other
screens but have not yet been thoroughly validated.
Viral proteins
E2 has been shown to bind to several other PV proteins. Best
characterized is the interaction between E1 and E2 (reviewed in
Bergvall et al., this issue). E1 is the replication initiation helicase
and E2 is the helicase loader (Frattini and Laimins, 1994; Mohr
et al., 1990). After loading, E2 is displaced from the origin and E1
forms a hexameric helicase that encircles the origin (Sanders and
Stenlund, 1998; Schuck and Stenlund, 2005; Sedman and Stenlund,
1998; Titolo et al., 2000). E1 contains both a speciﬁc DNA binding
domain that contacts the E1 binding sequence in the origin (Chen
and Stenlund, 1998; Saraﬁ and McBride, 1995) and a non-speciﬁc
DNA binding domain in the helicase region that contacts the
ﬂanking A/T rich sequences (Schuck and Stenlund, 2006). The non-
speciﬁc DNA binding region is masked in the E1-E2 complex and
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(Stenlund, 2003).
The N-terminal domain of E2 interacts with a large C-terminal
region of the E1 protein containing the origin binding region and
helicase (Leng et al., 1997; Muller and Sapp, 1996; Saraﬁ and
McBride, 1995; Yasugi et al., 1997). Mutations in the ﬁrst N-
terminal alpha-helix of E2, or antibodies that bind to this region,
will disrupt the E1-E2 complex (Baxter and McBride, 2005;
Hibma et al., 1995). Probably the best characterized interaction
residue is glutamate 39, which (as shown in Table 3) when
mutated to alanine abrogates the interaction with E1 in some E2
proteins (Ferguson and Botchan, 1996; Sakai et al., 1996). How-
ever, most useful is a structure of the HPV18 E2 transactivation
domain in complex with residues 428–631 from the helicase
domain of the 657 residue E1 protein (Abbate et al., 2004). As
shown in Fig. 10, this region of E1 primarily interacts with the
bundle of three alpha-helices on the concave surface of the
transactivation domain, the fulcrum region and the short beta-
sheets between helices 2 and 3. Glutamate 39 (or 43 in HPV18 E2)
forms a buried salt bridge with the highly conserved residue
arginine 454 in E1. Notably, in BPV1 E1, the equivalent residue is
an asparagine (ibid.).
In certain circumstances, the DNA binding domains of E1 and
E2 can interact while they are bound to adjacent sites on the origin
(Chen and Stenlund, 2000). This interaction might only occur in
viruses such as BPV1 where the E1 and E2 sites are only 3bp apart.
It is not completely essential as the E2 DNA binding site can be
moved further away without detriment (Gillitzer et al., 2000).
Furthermore, The E2 DNA binding domain and origin binding site
can be replaced with those of Gal4 and maintain a functional
origin (Winokur and McBride, 1996). The residues on the DNA
binding domain that interact with E1 are shown in Fig. 11A.Table 3
The values for each function were estimated from the references listed. (1) Brokaw et al.,
al., 2005; (6) Senechal et al., 2007; (7) Jeckel et al., 2002; (8) Cooper et al., 1998; (9) Saka
and Botchan, 1996; (13) Breiding et al., 1996; (14) DiMaio & Settleman, 1988; (15) Dow
Residue Virus Mutation Transcription Brd4
binding
Transient
replication
E1
binding
Episom
replica
WT +++ +++ +++ +++ +++
R37 BPV1 R37K +++ +++ , +++ ++
R37A + , - , ++ + ++, + , +++ +++
SFPV1 R37K +++ ++ +++
R37A + +/- +
HPV11 R37K + -
R37A +
HPV16 R37A - +/- + +++
HPV31 R37K - + +++ +
E39 BPV1 E39D - , - +/-, ++ ts ++
E39A + ,+++ , ++ ,
+++
++ +++, ++, ++
+, +
+++
E39Q +++ ++ ++ +++
E39G - +++
SFPV1 E39Q +++ +/-
E39A ++ +/-
HPV11 E39D ++ +
E39A + +++
HPV16 E39A +++ +++ - -
HPV31 E39Q +++ ++ -
I73 BPV1 I73N - +++
I73L + +++, +++ +++
I73A ++, - + ++, +++ +++
SFPV1 I73L + ++ ++
HPV16 I73A - - +++ +++
HPV31 I73L - - +++ +++
tsE2 BPV1 ins 180-
181
- -
W130 BPV1 W130R ++ +++ +++ -E2 also interacts with the minor capsid protein L2. The L2
protein colocalizes with ND10 nuclear bodies and recruits the E1
and E2 proteins to this location. Initially it was thought that this
was important for viral genome packaging (Day et al., 1998) but
further studies indicated that this association is important for
establishment of infection (Day et al., 2004). L2 can inhibit the
transactivation, but not the replication, function of E2 (Heino et al.,
2000; Okoye et al., 2005). The N-terminal 50 amino acids of L2
interact directly with E2 but L2 residues 301–400 are also required
to repress E2-mediated transcription (Okoye et al., 2005). The ﬁrst
50 residues of E2, and sequences spanning the hinge region,
interact with the L2 protein (Heino et al., 2000).
E2 interacts with several other PV proteins, though the exact role
in the life cycle is not ﬁrmly established. Smal and colleagues ﬁnd
that the N-terminus of E7 interacts with the DNA recognition helix
of HPV16 E2 whereas Gammoh et al. map an interaction between
the hinge of HPV16 E2 and the zinc binding region of E7 (Gammoh
et al., 2006; Smal et al., 2009). E2 can recruit E7 to mitotic
chromosomes in late mitosis (Gammoh et al., 2006). HPV16 and
HPV18 E6 and E6nI proteins directly interact with the C-terminal
domain of E2 through E6 residues 28–31 (Grm et al., 2005) and
changes the sub-nuclear location of both E2 and E6. The N-terminus
of HPV16 E2 also directly binds the E14E4 protein and relocates E2
from the nucleus to the cytoplasm (Davy et al., 2009).Mutations that inactivate speciﬁc functions of the E2 proteins
Mutations in the DNA binding domain
Fig. 11A shows the BPV1 E2 DNA binding domain from PDB:1DBD.
This is the only structure to date that contains the entire 100 amino1996; (2) Zheng et al., 2005; (3) Abroi et al., 1996; (4) Abroi et al., 2004; (5) Baxter et
i et al., 1996; (10) Schweigeret al., 2006; (11) Stubenrauch et al., 1998; (12) Ferguson
hanick et al., 1995; (16) Alderbor et al., 1992; (17) Parish et al., 2006.
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+++ +++ +++ +++
+++ transformation:- (1, 2)
++, ++ - (3-5)
papillomas: - (6, 7)
papillomas: - (6, 7)
(6, 8)
(8)
(9, 10)
- (6, 11)
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+++ . - - (3-5, 12)
+++ (5)
(13)
papillomas: - (6, 7)
papillomas: - (6, 7)
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(8)
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papillomas: - (6, 7)
(9, 10)
++ (6, 11)
+++ (14-16)
- ChLR1: - (17)
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R37
I73
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Q12
D13 D13
D122
D39
E90
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W33
S85
D174
D20
T93
D20
G50
K111/112
Fig. 12. Conserved Residues on the Surface of the E2 transactivation domain. The transactivation domain structure PDB: 1DTO (HPV16) was rendered in Pymol. Key,
conserved residues on the surface of the domain are indicated.
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on this structure are “landmarks” on this domain mapped in E2
proteins from a number of different PV types. In red is the region in
BPV1 E2 that interacts with E1 when both proteins are bound to
adjacent sites: mutations in BPV1 E2 388, 390 and 401 impaired
cooperative E1-E2 binding and replication (Gillitzer et al., 2000). The
same helix interacts with p53, and shown in orange are residues that
when mutated (HPV16 D338, E340, W341, D344) reduce p53 binding,
inhibition of replication by p53 and E2-mediated apoptosis, yet they
do not affect replication (Brown et al., 2008). Other residues shown
have been mutated and are discussed elsewhere: potential SUMO
modiﬁcation sites (gray, Section 6.3); cdk2 phosphorylation sites
(yellow, Section 6.1); the tryptophan bridge (cyan, Section 4.2); and
the redox cysteine (blue, Section 6.4). Also shown are key residues in
the recognition helix (in purple). Fig. 11B lists the DNA binding
phenotype of amino acid residue substitutions in the recognition helix
of BPV1 and HPV11.
Mutations in the transactivation domain
Early studies involved the generation of deletions or amino acid
insertions in E2. For the most part, these were not informative
because of the precise fold of the conserved domains and most
resulting proteins were non-functional. However, there have been
several extensive mutational analyses of the E2 transactivation
domain (Abroi et al., 1996; Baxter et al., 2005; Breiding et al., 1996;
Brokaw et al., 1996; Cooper et al., 1998; Ferguson and Botchan,
1996; Smith et al., 2006). These studies have been reviewed and
compared previously (McBride and Myers, 1997) and this analysis
is still available on the PaVE website. Most of the studies (except
(Baxter et al., 2005)) were undertaken before the structure of the
N-terminal domain was solved. The structure revealed that many
of the highly conserved residues were internal and/or had a
structural role (Antson et al., 2000). Therefore, only mutations in
conserved, surface residues are considered here. There have been
additional studies further analyzing the phenotypes of these
mutations in mitotic chromosomal binding (Abroi et al., 2004;
Baxter et al., 2005; Zheng et al., 2005), Brd4 binding (Senechal
et al., 2007), episomal maintenance and late transcription and
replication (Stubenrauch et al., 1998a), papilloma induction in
rabbits (Jeckel et al., 2002), and binding to cellular proteins ChLR1,
Mklp2 and AMF1 (Breiding et al., 1997; Parish et al., 2006).When the 241 E2 proteins currently hosted on the PaVE website
are compared, there are 51 residues in the transactivation domain that
are identical in 85% or more proteins, or have very conservative
alternates. About half of these residues are exposed on the surface and
are shown on the structure of the HPV16 transactivation domain
shown in Fig. 12. Table 3 lists the phenotype of some of the best
studied mutations. For example, residues R37 and I73 are involved in
transcriptional regulation and Brd4 binding whereas E39 is important
for replication and E1 interaction. Mutations in these residues are
thought to separate the replication and transcription functions of E2.
However, as can be seen in Table 3, caution should be observed as the
actual amino acid substitution can result in different phenotypes and
varying results with different PVs.
It should be noted that the structural fold of the E2 transactiva-
tion domain is quite sensitive to mutation and many amino acid
substitutions are temperature sensitive (ts). A ts protein was
generated by the insertion of the sequence PRSR between residues
180 and 181 of BPV1 E2 (DiMaio and Settleman, 1988). At the non-
permissive temperature, this protein cannot support transactiva-
tion, episomal genome replication or transformation (DiMaio and
Settleman, 1988), but is competent for transient replication
(Alderborn et al., 1992). This ts E2 has been used in several studies
to delineate the functions of E2 in speciﬁc processes such as
repression of E6 and E7 gene expression (Dowhanick et al., 1995)
and vegetative viral DNA replication (Alderborn et al., 1992). In
fact, many mutations in the E2 transactivation domain are tem-
perature sensitive (Baxter et al., 2005; Ferguson and Botchan,
1996; Zheng et al., 2005). E2 proteins that are ts for interaction
with mitotic chromosomes can be induced to bind host chromo-
somes at lower temperatures or when cells are treated with agents
that promote protein folding (Zheng et al., 2005).
Mutations in the hinge region
The hinge region is not required for transcriptional regulation
or replication, though a certain amount of linker sequence is
required to prevent steric hindrance between the N and C-
terminal domains (Winokur and McBride, 1992). The hinge of
HPV11 is important for nuclear localization and nuclear matrix
association and substitution of residues 238 RKRAR 242 with
alanines disrupts this localization. The hinge region of the delta-
PVs contains the major phosphorylation sites at residues 298 and
A.A. McBride / Virology 445 (2013) 57–7974301 and a phosphorylation dependent conformational switch that
targets E2 for degradation (Penrose et al., 2004). Penrose and
colleagues present a detailed mutational analysis of this region
(2004). Likewise, the hinge of HPV8 E2 contains a phosphorylation
site at serine 253 that stabilizes E2 and promotes its association
with chromatin (Sekhar et al., 2010). Sekhar and colleagues
present a detailed mutational analysis of this region (2010).
Mutations in the E8 moiety of E84E2
Stubenrauch et al. conducted an alanine scanning analysis
through the entire E8 portion of the E84E2 protein (Stubenrauch
et al., 2001). This showed that tryptophan 6 and lysine 7 are the
main determinants of repressor function. A triple mutation KWK
(residues 5, 6, 7 mutated to alanine) has been used in many studies
of E84E2 function (Ammermann et al., 2008; Powell et al., 2010;
Stubenrauch et al., 2007).Conclusions
The PV E2 proteins are remarkable, multifunctional proteins
that are involved in many key viral and cellular processes. The
availability of over 240 versions of these proteins, which have
slowly evolved for millions of years in speciﬁc anatomical niches
within each host species, can provide great insight into protein
function and evolution.Acknowledgments
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